Baltimore– Biotechnology startup Infinity Bio has raised $8 million in a Series A funding round led by Illumina Ventures, with additional backing from PTX Capital, Blackbird BioVentures, and the Propel Baltimore Fund. The company said the funds will fuel the expansion of its commercial operations, accelerate development of its immune profiling platform, and support the launch of new services.
As part of its strategic growth, Infinity Bio has also acquired the assets of Serimmune, Inc., a California-based company founded in 2014 that specializes in antibody reactome services. The acquisition aims to enhance Infinity’s technological capabilities and service offerings, particularly through its proprietary MIPSA™ platform.
CEO Joy Nassif described the fundraising as a major milestone in the company’s effort to redefine how immune system data is accessed and understood. “We are building the foundation for a new category of immune system intelligence: accessible, scalable, and deeply informative,” Nassif said.
Founded in 2023, Infinity Bio operates out of a 9,000-square-foot lab in Baltimore. Its core services — including HuSIGHT™, VirSIGHT™, AllerSIGHT™, and MuSIGHT™ — enable high-throughput, high-resolution analysis of antibody responses. These services are aimed at clients in academia, government, and biopharma, supporting applications in biomarker discovery, research, and drug development.
The company is preparing to launch new MIPSA™-based services later in 2025, including EnviroSIGHT™, which will further broaden its capabilities in immune profiling.
Infinity Bio’s Chief Science Officer, Ben Larman, who is also an associate professor of pathology at Johns Hopkins University, emphasized the value of the company’s approach. “Our technologies illuminate the complex interplay between inflammation, immunity, and health,” he said. “We’re creating a limitless capacity to generate high-quality antibody reactome data.”
Malek Faham, MD, PhD, Chief Scientist at Illumina Ventures, praised Infinity’s scientific potential. “This enhanced, more comprehensive technology is a game changer for biomedical researchers who can use it for a broad range of applications to accelerate their discoveries,” he said.
Matt Hellauer, Managing Partner at PTX Capital and Chairman of Infinity Bio, said the company aims to become a global leader in immune system data. “Partnering with a world-class firm like Illumina Ventures reinforces that vision and positions Infinity to scale as the category leader in antibody reactome profiling,” he said.
